This study aimed to determine the effect of oral hesperidin supplement on glycemic and lipidemic risk factors, visceral adiposity index, serum levels of oxidant, inflammatory and oxidative DNA damage markers in type 2 diabetic patients. In this 2 phase double blind clinical trial 64 patients would be randomly allocated to the supplement or placebo groups using random number tables. neither the patients nor administrator of the treatment know which capsules are being received. All patients will provide 10 ml fasting venous blood samples at the beginning and at the end of the study. Data on dietary, physical activity and anthropometric characteristics and body fat percentage will be recorded. Diabetic Patients will be selected among those who are referred to the Diabetes clinic of Ahvaz Golestan Hospital with at least 3 years history of diabetes and taking oral hypoglycemic agents without a history of heart, liver and kidney disease or other endocrine disorders and will consume 600 milligrams of hesperidin supplement or placebo capsules for 6 weeks and will be followed weekly during the intervention period. body fat percentage, body mass index, glycemic and lipidemic indexes, including fasting glucose, insulin, serum fructosamine, total cholesterol, HDL-C, LDL –C, triglycerid and visceral adiposity index, and serum levels of total antioxidant capacity, malondialdehyde and the inflammatory marker as TNF-α, interleukin-6 (IL-6), hs- CRP and oxidative DNA damage will be detected in all patients.